Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patientss: a retrospective analysis

• Autores: T. Korkmaz, S. Seber, U. Kefeli, E. Sari, M. Canhoroz, Basak Oven Ustaalioglu, Mahmut Gumus, E. Yildirim, N. Yasar, D. Aydin, O. Balvan, N. Sener, S. Yuksel, A. Mert, O. Polat, F. Yumuk, Ozkan Kanat, N. S. Turhal
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 7, 2013, págs. 535-540
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment.

    Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers.

    Results Median age of group was 58. 82 % had an ECOG PS of 0¿1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate.

    Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.